TY - JOUR
T1 - Pharmacological treatment strategies in obsessive compulsive disorder
T2 - A cross-sectional view in nine international OCD centers
AU - Van Ameringen, Michael
AU - Simpson, William
AU - Patterson, Beth
AU - Dell'Osso, Bernardo
AU - Fineberg, Naomi
AU - Hollander, Eric
AU - Hranov, Luchezar
AU - Hranov, Georgi
AU - Lochner, Christine
AU - Karamustafalioglu, Oguz
AU - Marazziti, Donatella
AU - Menchon, Jose M.
AU - Nicolini, Humberto
AU - Pallanti, Stefano
AU - Stein, Dan J.
AU - Zohar, Joseph
N1 - Funding Information:
Dr. Zohar reports he is an employee of Chaim Sheba Medical Center, and has received consulting fees from Lundbeck, Pfizer, grants and consulting fees from Servier, grants and consulting fees from Roche, consulting fees from Pfizer and Eli Lilly. He has received grants from National Institute of Mental Health, and the Department of Defense. He is on advisory boards of Abbot, Actelion, Astra Zeneca, Lundbeck, Roche, Servier and Pfizer.
Funding Information:
This project was coordinated by the International College of OCD Spectrum Disorders and by the European College of Neuropsycho-pharmacology Research Networks Initiative.
PY - 2014/6
Y1 - 2014/6
N2 - Objective: It is unknown what next-step strategies are being used in clinical practice for patients with obsessivecompulsive disorder (OCD) who do not respond to first-line treatment. As part of a cross-sectional study of OCD, treatment and symptom information was collected. Method: Consecutive OCD out-patients in nine international centers were evaluated by self-report measures and clinical/structured interviews. OCD symptom severity was evaluated by the Yale Brown Obsessive Compulsive Scale (YBOCS) and Clinical Global ImpressionSeverity Scale (CGI-S). Clinical response to current treatment was evaluated by the CGI-Improvement Scale (CGI-I ≤ 2). Results: In total, 361 participants reported taking medication; 77.6% were taking a selective serotonin reuptake inhibitor; 50% reported use of at least one augmentation strategy. Antipsychotics were most often prescribed as augmenters (30.3%), followed by benzodiazepines (24.9%) and antidepressants (21.9%). No differences in OCD symptom severity were found between patients taking different classes of augmentation agents. Conclusions: Results from this international cross-sectional study indicate that current OCD treatment is in line with evidence-based treatment guidelines. Although augmentation strategies are widely used, no significant differences in OCD symptom severity were found between monotherapy and augmentation or between different therapeutic agents.
AB - Objective: It is unknown what next-step strategies are being used in clinical practice for patients with obsessivecompulsive disorder (OCD) who do not respond to first-line treatment. As part of a cross-sectional study of OCD, treatment and symptom information was collected. Method: Consecutive OCD out-patients in nine international centers were evaluated by self-report measures and clinical/structured interviews. OCD symptom severity was evaluated by the Yale Brown Obsessive Compulsive Scale (YBOCS) and Clinical Global ImpressionSeverity Scale (CGI-S). Clinical response to current treatment was evaluated by the CGI-Improvement Scale (CGI-I ≤ 2). Results: In total, 361 participants reported taking medication; 77.6% were taking a selective serotonin reuptake inhibitor; 50% reported use of at least one augmentation strategy. Antipsychotics were most often prescribed as augmenters (30.3%), followed by benzodiazepines (24.9%) and antidepressants (21.9%). No differences in OCD symptom severity were found between patients taking different classes of augmentation agents. Conclusions: Results from this international cross-sectional study indicate that current OCD treatment is in line with evidence-based treatment guidelines. Although augmentation strategies are widely used, no significant differences in OCD symptom severity were found between monotherapy and augmentation or between different therapeutic agents.
KW - Obsessive-compulsive disorder
KW - augmentation
KW - effectiveness
KW - international
KW - medication
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=84901608080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901608080&partnerID=8YFLogxK
U2 - 10.1177/0269881113517955
DO - 10.1177/0269881113517955
M3 - Article
C2 - 24429223
AN - SCOPUS:84901608080
SN - 0269-8811
VL - 28
SP - 596
EP - 602
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 6
ER -
